Key result
The dominant EDN2 A allele was associated with an increased risk of atrial fibrillation in patients with hypertrophic cardiomyopathy.
Why the study?
Does the EDN2 A985G polymorphism increase the risk of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Cohort (n=110)
Does the EDN2 A985G polymorphism increase the risk of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
The EDN2 A985 allele, along with the ACE insertion/insertion genotype and increased QRS dispersion, is an independent risk factor for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy.
BACKGROUND: It was recently suggested that the angiotensin-converting enzyme insertion/insertion genotype, which is considered to be protective against cardiovascular disease, was a significant risk factor for atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM). The aim of this study was to investigate the association between the endothelin-2 (EDN2) A985G polymorphism and AF in patients with HCM. METHODS AND RESULTS: The EDN2 A985G polymorphism (rs 5800) was genotyped in 110 patients with HCM who had no clinically documented AF before medical treatment. The distribution of the EDN2 genotypes (G/G, G/A, and A/A) was 77.3%, 19.1%, and 3.6%, respectively. The EDN2 A allele frequency was 0.21 in 26 patients who subsequently developed AF during long-term follow-up and 0.11 in 84 patients who remained in sinus rhythm. The distribution of genotypes of the dominant EDN2 A allele between the two groups was significantly different by chi-square analysis (42.3% vs 16.7%, p=0.014). In a multivariate model, the A985 allele of the EDN2 gene was associated with increased adjusted risk for the occurrence of AF (p=0.018). CONCLUSION: The EDN2 A985 allele, which is considered to be protective in cardiovascular disease, may be a risk factor for AF in patients with HCM.
No takes yet. Share an insight, caveat, or question.
Nagai et al. (2007) conducted a cohort in Hypertrophic cardiomyopathy (n=110). EDN2 A985G polymorphism (dominant EDN2 A allele) vs. No dominant EDN2 A allele was evaluated on Occurrence of atrial fibrillation (p=0.014). The dominant EDN2 A allele was associated with an increased risk of atrial fibrillation in patients with hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: